Ultragenyx Pharmaceutical (NASDAQ:RARE) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Friday.

A number of other equities analysts have also recently weighed in on the stock. ValuEngine raised shares of Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 1st. Cowen reaffirmed a “buy” rating and set a $69.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 26th. Raymond James reaffirmed an “outperform” rating and set a $80.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Friday, February 22nd. Citigroup upped their price target on shares of Ultragenyx Pharmaceutical from $54.00 to $62.00 and gave the stock a “neutral” rating in a research note on Thursday, February 21st. Finally, Credit Suisse Group reaffirmed a “hold” rating and set a $59.00 price target on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 20th. Six research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $76.16.

NASDAQ:RARE opened at $68.27 on Friday. Ultragenyx Pharmaceutical has a fifty-two week low of $37.44 and a fifty-two week high of $90.98. The firm has a market cap of $3.50 billion, a PE ratio of -9.24 and a beta of 2.21.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, February 19th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.74) by $0.01. Ultragenyx Pharmaceutical had a negative net margin of 383.75% and a negative return on equity of 35.26%. The business had revenue of $16.26 million for the quarter, compared to analysts’ expectations of $13.30 million. Research analysts predict that Ultragenyx Pharmaceutical will post -6.79 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in RARE. Capital International Investors boosted its position in shares of Ultragenyx Pharmaceutical by 20.9% in the 3rd quarter. Capital International Investors now owns 4,359,891 shares of the biopharmaceutical company’s stock worth $332,834,000 after buying an additional 755,127 shares in the last quarter. Capital World Investors lifted its holdings in Ultragenyx Pharmaceutical by 75.8% in the 3rd quarter. Capital World Investors now owns 1,461,390 shares of the biopharmaceutical company’s stock valued at $111,563,000 after purchasing an additional 630,088 shares in the last quarter. Norges Bank purchased a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at about $16,047,000. D. E. Shaw & Co. Inc. lifted its holdings in Ultragenyx Pharmaceutical by 5,859.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 321,834 shares of the biopharmaceutical company’s stock valued at $13,993,000 after purchasing an additional 316,434 shares in the last quarter. Finally, Macquarie Group Ltd. purchased a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at about $20,045,000. Institutional investors and hedge funds own 99.20% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Read More: Book Value Per Share in Stock Trading

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.